59510
甲基磺酸
suitable for HPLC, LiChropur™, ≥99.5% (T)
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
线性分子式:
CH3SO3H
化学文摘社编号:
分子量:
96.11
UNSPSC Code:
12161700
NACRES:
NB.21
PubChem Substance ID:
EC Number:
200-898-6
Beilstein/REAXYS Number:
1446024
MDL number:
vapor density
3.3 (vs air)
Quality Level
vapor pressure
1 mmHg ( 20 °C)
assay
≥99.5% (T)
form
liquid
quality
LiChropur™
technique(s)
HPLC: suitable
color
APHA: ≤35
refractive index
n20/D 1.428-1.430, n20/D 1.429 (lit.)
bp
167 °C/10 mmHg (lit.)
mp
17-19 °C (lit.)
density
1.481 g/mL at 25 °C (lit.)
suitability
corresponds to standard for HPLC
SMILES string
O=S(O)(C)=O
InChI
1S/CH4O3S/c1-5(2,3)4/h1H3,(H,2,3,4)
InChI key
AFVFQIVMOAPDHO-UHFFFAOYSA-N
Packaging
透明的硼硅酸盐玻璃，高耐水解性（I 型）
Analysis Note
紫外光谱测试符合要求
Legal Information
LiChropur is a trademark of Merck KGaA, Darmstadt, Germany
Still not finding the right product?
Explore all of our products under 甲基磺酸
signalword
Danger
Hazard Classifications
Acute Tox. 4 Dermal - Acute Tox. 4 Oral - Eye Dam. 1 - Met. Corr. 1 - Skin Corr. 1B - STOT SE 3
target_organs
Respiratory system
存储类别
8A - Combustible corrosive hazardous materials
wgk
WGK 1
flash_point_f
372.2 °F - closed cup
flash_point_c
189 °C - closed cup
法规信息
危险化学品
此项目有
Mohammad M Fares et al.
Biomaterials science, 6(11), 2938-2950 (2018-09-25)
The design of new hydrogel-based biomaterials with tunable physical and biological properties is essential for the advancement of applications related to tissue engineering and regenerative medicine. For instance, interpenetrating polymer network (IPN) and semi-IPN hydrogels have been widely explored to
Adnan H Mahmood et al.
International journal of pharmaceutics, 481(1-2), 71-78 (2015-02-01)
To introduce better antibiotics for the treatment of some infectious diseases in sheep and to expand the range of antibiotics available for veterinary medicine, pharmacokinetics of two antibiotics marbofloxacin (MBX) and trovafloxacin (TVX) were investigated in sheep after intramuscular injection.
Chris Twelves et al.
Breast cancer research and treatment, 148(3), 553-561 (2014-11-09)
Data from two phase 3 studies of eribulin were pooled in analyses initially requested by the European Medicines Agency to assess whether specific patient subgroups, previously treated with an anthracycline and a taxane, benefited from eribulin. Study 305/EMBRACE included women
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| 59510-1ML-KC | 04061838089489 |
| 59510-10X1ML | 04061832644028 |
| 59510-1ML | 04061838196163 |